Drugs / DB-1202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05785728 | Jun 2023 → Feb 2024 | neoplasm | DualityBio Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DB-1202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05785728 ↗ |
| Route | Intravenous | “Administered I.V.” NCT05785728 ↗ |